TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12951643

Group type: EXPERIMENTAL
Intervention: Participation in a clinical trial (qualification phase of a Good Clinical Practice trial)
Number of subjects: 0
Study: 10863219

Group type: EXPERIMENTAL
Intervention: Fexofenadine 60 mg twice daily
Number of subjects: 169
Study: 9190093

Group type: EXPERIMENTAL
Intervention: Self-efficacy information intervention (written information package with discussion, list of questions for physician, audiotape of medical consultation)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Written information package alone (control group)
Number of subjects: 60
Study: 1414966

Group type: EXPERIMENTAL
Intervention: Diet high in monounsaturated fatty acids, enriched with avocado (AE)
Number of subjects: 15

Group type: COMPARATOR
Intervention: High-complex-carbohydrate diet (AHA-III)
Number of subjects: 15
Study: 2882046

Group type: EXPERIMENTAL
Intervention: Fixed combination of pilocarpine 2% and metipranolol 0.1%
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pilocarpine 2% alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Metipranolol 0.1% alone
Number of subjects: 0
Study: 30613061

Group type: EXPERIMENTAL
Intervention: Intergenerational Exchange Program (IGEP) for older adults
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Intergenerational Exchange Program (IGEP) for preschool children
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (older adults)
Number of subjects: 42
Study: 26862857

Group type: EXPERIMENTAL
Intervention: Capecitabine or UFT plus radiotherapy (RT)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Capecitabine or UFT plus cetuximab plus RT
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: High baseline plasma miR‐21
Number of subjects: 17
Study: 24909509

Group type: EXPERIMENTAL
Intervention: Gemcitabine/oxaliplatin (GEMOX) plus erlotinib
Number of subjects: 268

Group type: COMPARATOR
Intervention: Gemcitabine/oxaliplatin (GEMOX) alone
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Metabolic tumor volume (MTV) as a prognostic factor
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Maximum standardized uptake value (SUVmax)
Number of subjects: 268
Study: 22103795

Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy (CBT)
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy (IPT)
Number of subjects: 177
Study: 20109331

Group type: EXPERIMENTAL
Intervention: CD gel
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 40
Study: 18096307

Group type: EXPERIMENTAL
Intervention: Photodynamic diagnosis (PDD) with hexaminolevulinate (Hexvix) solution
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Photodynamic diagnosis (PDD)
Number of subjects: 0
Study: 15869144

Group type: COMPARATOR
Intervention: Conventional indicators of hypoperfusion (Group 1)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Gastric tonometry-derived estimates of splanchnic hypoperfusion (Group 2)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Therapies aimed at optimizing splanchnic perfusion (Group 3)
Number of subjects: 151
Study: 12873920

Group type: EXPERIMENTAL
Intervention: IV test dose (0.1 mL/kg) consisting of 1% lidocaine with 1:200,000 epinephrine (epinephrine 0.5 microg/kg)
Number of subjects: 32

Group type: COMPARATOR
Intervention: IV saline 0.1 mL/kg
Number of subjects: 32
Study: 10723498

Group type: EXPERIMENTAL
Intervention: Once daily didanosine plus twice daily stavudine (group A)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Twice daily didanosine plus twice daily stavudine (group B)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Comparison of both groups
Number of subjects: 84
Study: 7857095

Group type: EXPERIMENTAL
Intervention: Intraperitoneal chemotherapy (75 mg/body cisplatin, 150 mg/body etoposide, 10 mg/body mitomycin C, and oral 5-FU)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Intraperitoneal chemotherapy
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control group (not specified treatment)
Number of subjects: 8
Study: 1958432

Group type: EXPERIMENTAL
Intervention: Gemfibrozil treatment with good medication compliance (≥90% capsule consumption)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gemfibrozil treatment with good medication compliance (≥90% positive gemfibrozil analyses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gemfibrozil treatment with good medication compliance (good compliance according to both digoxin marker measurements)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gemfibrozil treatment with poor medication compliance (<50% capsule consumption)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gemfibrozil treatment with poor medication compliance (<50% positive gemfibrozil analyses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gemfibrozil treatment with poor medication compliance (poor results in both digoxin marker measurements)
Number of subjects: 0
Study: 6890361

Group type: EXPERIMENTAL
Intervention: Acebutolol 300 mg
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Acebutolol 100 mg
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Acebutolol 500 mg
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Acebutolol 300 mg and 500 mg
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Acebutolol 200 mg
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Acebutolol 100-300 mg
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Acebutolol (any dose)
Number of subjects: 19
Study: 30921503

Group type: EXPERIMENTAL
Intervention: OLZ/SAM (10 mg OLZ/10 mg SAM) in fed conditions
Number of subjects: 36

Group type: COMPARATOR
Intervention: OLZ/SAM (10 mg OLZ/10 mg SAM) in fasted conditions
Number of subjects: 36
Study: 26936430

Group type: EXPERIMENTAL
Intervention: Brush allodynia
Number of subjects: 20

Group type: COMPARATOR
Intervention: Semmes‐Weinstein monofilament
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Capsaicin (Zostrix 0.075%)
Number of subjects: 20
Study: 25368372

Group type: EXPERIMENTAL
Intervention: Rasagiline, 1mg/d (n = 31)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (n = 29)
Number of subjects: 60
Study: 23851908

Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV) treatment
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: RBV concentration at week 8
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Optimal cut-off value of week 8 RBV concentration
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Optimal cut-off values at weeks 1, 2, or 4
Number of subjects: 61
Study: 21736853

Group type: EXPERIMENTAL
Intervention: Strawberry beverage
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 24
Study: 19885051

Group type: EXPERIMENTAL
Intervention: Multimodal pain control protocol
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional pain control protocol
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 16443502

Group type: EXPERIMENTAL
Intervention: GDM group (100 women with abnormal OGTT)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Gly482Ser and Thr394Thr polymorphisms of the PGC‐1 gene
Number of subjects: 200

Group type: COMPARATOR
Intervention: Different haplotype combinations of the two loci
Number of subjects: 200
Study: 15001247

Group type: COMPARATOR
Intervention: Conventional radiotherapy (with rectangular fields) to a dose of 66 Gy
Number of subjects: 199

Group type: COMPARATOR
Intervention: Three-dimensional conformal radiotherapy to a dose of 66 Gy
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Irradiated rectum volume at 60 Gy
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Dose levels between 25 Gy and 60 Gy
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Relative DVHs of the rectal wall excluding the anal region at 60 Gy
Number of subjects: 199
Study: 11669434

Group type: EXPERIMENTAL
Intervention: Reverse technique (Group B)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Standard technique (Group A)
Number of subjects: 67
Study: 9608433

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EXP 3174
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SL 91.0102‐90 DL
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: UP 269‐6
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control plasma
Number of subjects: 0
Study: 8017308

Group type: EXPERIMENTAL
Intervention: Iodixanol
Number of subjects: 200

Group type: COMPARATOR
Intervention: Iohexol
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Both agents
Number of subjects: 200
Study: 2689471

Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Acetaminophen 1000 mg
Number of subjects: 184

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 184
Study: 773907

Group type: EXPERIMENTAL
Intervention: Taurolin 2% (formaldehyde releasing antimicrobial)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Vantocil 0.1% (polybiguanide)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Amine fluoride 0.025%
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 16
Study: 7225912

Group type: EXPERIMENTAL
Intervention: Lidocaine 0.75%
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25%
Number of subjects: 7
Study: 30635038

Group type: EXPERIMENTAL
Intervention: Pulmonary exercise group (PG)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Resistance exercise group (RG)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined pulmonary exercise and resistance exercise group (PRG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (control group, CG)
Number of subjects: 0
Study: 29131887

Group type: EXPERIMENTAL
Intervention: Breastfeeding promotion intervention
Number of subjects: 13557

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 13557
Study: 26848151

Group type: EXPERIMENTAL
Intervention: Veliparib 300mg BID
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Veliparib 200mg BID + Mitomycin C (10mg/m2 every 28 days)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Veliparib alone or with MMC
Number of subjects: 61
Study: 25239483

Group type: EXPERIMENTAL
Intervention: Live attenuated SA 14-14-2 JE vaccine manufactured in a new GMP facility
Number of subjects: 818

Group type: COMPARATOR
Intervention: Live attenuated SA 14-14-2 JE vaccine manufactured in the original facility
Number of subjects: 818
Study: 21626049

Group type: EXPERIMENTAL
Intervention: PDXG regimen (cisplatin, docetaxel, capecitabine, gemcitabine)
Number of subjects: 105

Group type: COMPARATOR
Intervention: PEXG regimen (cisplatin, epirubicin, capecitabine, gemcitabine)
Number of subjects: 105
Study: 19132807

Group type: EXPERIMENTAL
Intervention: Multifaceted intervention based on healthcare management agreements including periodic educational meetings and economic incentives.
Number of subjects: 0
Study: 17984738

Group type: EXPERIMENTAL
Intervention: PEG 3350 laxative (MiraLax) 17 g per day for 28 days
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: PEG 3350 laxative
Number of subjects: 100
Study: 12950711

Group type: EXPERIMENTAL
Intervention: Gabapentin (mean dose = 888 +/- 418 mg at bedtime)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Trazodone (mean dose = 105 +/- 57 mg at bedtime)
Number of subjects: 50
Study: 10786962

Group type: EXPERIMENTAL
Intervention: Neutralizing antibody to tumor necrosis factor
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Recombinant interleukin 1 receptor antagonist
Number of subjects: 60
Study: 9561598

Group type: EXPERIMENTAL
Intervention: DTP-HB vaccine administered at 2, 4, and 6 months
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: DTP-HB vaccine
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: HB vaccination at birth followed by DTP-HB vaccine at 2, 4, 6, and 18 months
Number of subjects: 160
Study: 1606541

Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Radiation therapy
Number of subjects: 102

Group type: COMPARATOR
Intervention: Chemotherapy and Radiation therapy
Number of subjects: 102
Study: 4036270

Group type: EXPERIMENTAL
Intervention: 1.0 ml subcutaneously (SC)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 0.1 ml intradermally (ID)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 0.1 ml subcutaneously (SC)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 1.0 ml SC
Number of subjects: 60
Study: 30770726

Group type: EXPERIMENTAL
Intervention: TaGT genes
Number of subjects: 2387

Group type: EXPERIMENTAL
Intervention: BdGT genes
Number of subjects: 2387
Study: 28111208

Group type: EXPERIMENTAL
Intervention: Pre-operative intramuscular testosterone enanthate (2 mg/kg) administered in Group 2 (subdivided into Group 2A and Group 2B based on timing of surgery)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control group (Group 1)
Number of subjects: 94
Study: 25872501

Group type: EXPERIMENTAL
Intervention: Implementation of the management algorithm for tuberculosis diagnosis and treatment in intervention clinics.
Number of subjects: 24

Group type: COMPARATOR
Intervention: Standard of care in control clinics.
Number of subjects: 24
Study: 23665364

Group type: EXPERIMENTAL
Intervention: Percutaneous repair with the MitraClip device
Number of subjects: 279

Group type: COMPARATOR
Intervention: Conventional mitral valve surgery
Number of subjects: 279
Study: 21878162

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CBT)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Short-term psychodynamic psychotherapy (STPP)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 57
Study: 20031704

Group type: EXPERIMENTAL
Intervention: IVUS-directed therapy
Number of subjects: 800

Group type: COMPARATOR
Intervention: Angiography-directed therapy
Number of subjects: 800
Study: 17192504

Group type: EXPERIMENTAL
Intervention: HMR1766
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 15205487

Group type: EXPERIMENTAL
Intervention: Alpha tocopherol (50 mg daily)
Number of subjects: 24182

Group type: EXPERIMENTAL
Intervention: Beta carotene (20 mg daily)
Number of subjects: 24182

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24182
Study: 11252122

Group type: EXPERIMENTAL
Intervention: Pharmacologic therapies (aspirin and beta-adrenergic blocking agents)
Number of subjects: 183113

Group type: EXPERIMENTAL
Intervention: Coronary angiography and mechanical revascularization procedures
Number of subjects: 183113

Group type: COMPARATOR
Intervention: Major severity clinical events
Number of subjects: 183113

Group type: COMPARATOR
Intervention: Intermediate severity clinical events
Number of subjects: 183113

Group type: COMPARATOR
Intervention: Minor severity clinical events
Number of subjects: 183113
Study: 9161888

Group type: EXPERIMENTAL
Intervention: Methylphenidate treatment (4-week double-blind assessment)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Cognitive testing on methylphenidate
Number of subjects: 39
Study: 8120686

Group type: EXPERIMENTAL
Intervention: Practice and feedback on silicone breast models and women volunteers
Number of subjects: 156

Group type: COMPARATOR
Intervention: Lecture only
Number of subjects: 156
Study: 3122277

Group type: EXPERIMENTAL
Intervention: Misoprostol 50 mcg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Misoprostol 100 mcg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Misoprostol 200 mcg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Misoprostol (various doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 0
Study: 31401795

Group type: EXPERIMENTAL
Intervention: SNF472 (intravenous formulation of myo-inositol hexaphosphate) administered 3 times per week for 12 weeks
Number of subjects: 14
Study: 27893019

Group type: EXPERIMENTAL
Intervention: Blunt-needle injection (lidocaine, 2%; 27-gauge needle)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Sharp-needle injection
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Blunt-needle injection
Number of subjects: 44
Study: 26463698

Group type: EXPERIMENTAL
Intervention: Transdermal glyceryl trinitrate (GTN)
Number of subjects: 273

Group type: COMPARATOR
Intervention: No GTN
Number of subjects: 273
Study: 23822690

Group type: EXPERIMENTAL
Intervention: Creatine supplementation (50 mg/kg body wt)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 20630667

Group type: EXPERIMENTAL
Intervention: 1.5-T MRI
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 3.0-T MRI
Number of subjects: 40

Group type: COMPARATOR
Intervention: CT
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Intraobserver measurements
Number of subjects: 40
Study: 18824461

Group type: EXPERIMENTAL
Intervention: Early invasive strategy
Number of subjects: 1189

Group type: COMPARATOR
Intervention: Selective invasive strategy
Number of subjects: 1189

Group type: EXPERIMENTAL
Intervention: In-hospital revascularization
Number of subjects: 1189
Study: 16728246

Group type: EXPERIMENTAL
Intervention: New resin based obturation material with lateral condensation
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: New resin based obturation material with continuous wave obturation
Number of subjects: 80

Group type: COMPARATOR
Intervention: Gutta‐percha with lateral condensation
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Gutta‐percha with continuous wave obturation
Number of subjects: 80
Study: 14732409

Group type: EXPERIMENTAL
Intervention: Non-adjacent syllable patterns in speech streams
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-adjacent consonants and vowels with unrelated intervening segments
Number of subjects: 0
Study: 11208851

Group type: EXPERIMENTAL
Intervention: Zoledronic acid 4 mg
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Zoledronic acid 8 mg
Number of subjects: 287

Group type: COMPARATOR
Intervention: Pamidronate 90 mg
Number of subjects: 287
Study: 9509896

Group type: EXPERIMENTAL
Intervention: Anti-platelet treatment with dipyridamole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 0
Study: 8311489

Group type: EXPERIMENTAL
Intervention: CGS16949A 4 mg single dose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CGS16949A 8 mg single dose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CGS16949A 1 mg/day for 3 days (multiple administration)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CGS16949A 1 mg/day (after doubling the group size from 3 to 6 patients)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CGS16949A 2 mg/day (multiple administration)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CGS16949A 4 mg/day (multiple administration)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CGS16949A 8 mg/day (multiple administration)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CGS16949A 16 mg/day (multiple administration)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CGS16949A (multiple administration)
Number of subjects: 0
Study: 2898696

Group type: EXPERIMENTAL
Intervention: Single intramuscular injection of phenobarbitone (3.5 mg/kg)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 29472356

Group type: EXPERIMENTAL
Intervention: B-cell receptorhigh signature
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: High (>30%) Ki-67 staining
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: 6-gene signature related to B-cell receptor pathway
Number of subjects: 83
Study: 28327934

Group type: EXPERIMENTAL
Intervention: Pazopanib 800 mg/day
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Pazopanib 400 mg/day
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Pazopanib
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study: 26276968

Group type: EXPERIMENTAL
Intervention: Etanercept (ETN) 50 mg weekly for 12 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Etanercept (ETN)
Number of subjects: 0
Study: 23701382

Group type: EXPERIMENTAL
Intervention: 20 mm Hg LBPP
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 40 mm Hg LBPP
Number of subjects: 15
Study: 21968445

Group type: EXPERIMENTAL
Intervention: Quadrovax(®) vaccine
Number of subjects: 361

Group type: COMPARATOR
Intervention: TETRAct-Hib(®) vaccine
Number of subjects: 361
Study: 19917097

Group type: EXPERIMENTAL
Intervention: Surgical treatment (techniques chosen by the surgeon)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Standard non-surgical treatment
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Both groups (surgical and non-surgical)
Number of subjects: 250
Study: 16485576

Group type: EXPERIMENTAL
Intervention: Preserved endothelial function group (n = 10)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Endothelial dysfunction group (n = 10)
Number of subjects: 20
Study: 15273013

Group type: EXPERIMENTAL
Intervention: Entity theorists (believing traits are immutable)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Incremental theorists (believing traits are malleable)
Number of subjects: 0
Study: 10647074

Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg
Number of subjects: 159

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 159
Study: 9526175

Group type: EXPERIMENTAL
Intervention: 5% glucose solution containing 2g carnitine (Group B)
Number of subjects: 25

Group type: COMPARATOR
Intervention: 5% glucose‐enriched solution (Group A)
Number of subjects: 25
Study: 2202547

Group type: EXPERIMENTAL
Intervention: 50 mg atenolol and 20 mg nifedipine (1 capsule once daily)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 50 mg atenolol and 20 mg nifedipine (2 capsules once daily)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 50 mg atenolol and 20 mg nifedipine (1 capsule or 2 capsules once daily)
Number of subjects: 16
Study: 6783979

Group type: EXPERIMENTAL
Intervention: Intravenous (IV) administration of 800 mg valproate
Number of subjects: 0
Study: 31532044

Group type: EXPERIMENTAL
Intervention: Moringa stem meal (MSM) at 100 g/kg
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: Moringa stem meal (MSM) at 60 g/kg or less
Number of subjects: 1008

Group type: COMPARATOR
Intervention: Moringa stem meal (MSM) at 0 g/kg (control)
Number of subjects: 1008
Study: 30640284

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT) for 3 months
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (no training)
Number of subjects: 16